FDA approves high dose SPINRAZA for spinal muscular atrophy

March 30, 2026 7:30 AM

The U.S. Food and Drug Administration approved a high dose regimen of Biogen Inc.'s (NASDAQ: BIIB) SPINRAZA (nusinersen) for treating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found